OMass Therapeutics Raises $310 Million in Series C Funding
OMass Therapeutics, a biotech company specializing in drug discovery using native mass spectrometry, has successfully raised $310 million in a Series C funding round. This substantial investment aims to advance their research and development efforts. The company is based in Oxford, England.
Leading Investors and Support
The Series C round was led by Bain Capital Life Sciences, Forbion, and Novo Holdings. Other notable investors include British Business Bank, GV, Janus Henderson Investors, Jefferson Life Sciences, Northpond Ventures, Oxford Science Enterprises, Sanofi Ventures, SV Health Investors, Syncona, and the University of Oxford.
Executive Insights
Ros Deegan, the CEO of OMass Therapeutics, has been instrumental in driving the company’s strategic vision. The leadership team also includes Jonathan Hopper, Vice President of Platforms and a founder of the company.
Strategic Use of Funds
The newly acquired funds are expected to bolster OMass Therapeutics' drug discovery initiatives. While specific allocations were not detailed, such investments typically support scaling up operations, enhancing research capabilities, and potentially expanding into new markets.
OMass Therapeutics continues to make strides in the biotech industry with its innovative approach to drug discovery, leveraging cutting-edge technology to address critical healthcare challenges.